Patients’ quality of life in a Phase 4 real-world study of tildrakizumab in moderate-to-severe plaque psoriasis. (2023). SKIN The Journal of Cutaneous Medicine, 7(2), s135. https://doi.org/10.25251/skin.7.supp.135